Investor Relations

Investor Relations


Hospira, Inc. is the world's leading provider of injectable drugs and infusion technologies, and a global leader in biosimilars. Through its broad, integrated portfolio, Hospira is uniquely positioned to Advance Wellness™ by improving patient and caregiver safety while reducing healthcare costs. Hospira offers one of the broadest portfolios of generic acute-care and oncology injectables, as well as integrated infusion therapy and medication management solutions. It is the only North American company to offer biosimilars on market in Europe and Australia. Through its products, Hospira helps improve the safety, cost and productivity of patient care. Headquartered north of Chicago in Lake Forest, Ill., Hospira has approximately 19,000 employees worldwide and generated approximately $4.5 billion in net sales in 2014. Learn more >


View Pfizer Inc. and Hospira, Inc. February 5, 2015 Press Release
NEW! View Hospira’s Definitive Proxy Statement for the May 13, 2015 Special Meeting of Stockholders

Investor Presentations

Investor Presentations

Annual Report

2014 Annual Report

Stock Quote

Current Price$87.46
Change (%) Stock is Down 0.21 (0.24%)
Data as of 04/17/15 4:03 p.m. ET
Minimum 20 minute delay
Refresh quote

Stock Chart

Stock chart for: 03NA000000HSP

Recent News

04/13/15Hope for Greater Access for Patients to Biosimilar MedicinesPrinter Friendly Version
04/07/15Hospira to Announce First-Quarter 2015 Results on April 28, 2015Printer Friendly Version
03/30/15Hospira's INFLECTRA™ (Infliximab) Now Available in CanadaPrinter Friendly Version

Contact Information

Hospira Investor Relations

Tax Information for Shareholders

Tax/Cost Basis InformationDownload Documentation 
U.S. Tax Reporting StatementDownload Documentation 
Canadian Tax Reporting StatementDownload Documentation 

Transfer Agent

Computershare Investor Services
P.O. Box 43078
Providence, RI 02940-3078
800-821-1238 (US & Canada)
781-575-4677 (Outside the US & Canada)
Contact Site:

Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.